| dataset,property,endpoint_name,endpoint_id,n_measurements,n_antibodies,n_assays |
| FLAb2.0,aggregation,AC-SINS shift (nm),endpoint_be054f62cfa7b5bac93c,13,13,1 |
| FLAb2.0,aggregation,AC-SINS Δλmax (nm),endpoint_1ca39067897034a99802,179,179,2 |
| FLAb2.0,aggregation,Accelerated stability slope,endpoint_ac2080f658aee45a8ce4,136,136,1 |
| FLAb2.0,aggregation,CIC column K,endpoint_970984cf6e7786211ffe,43,43,1 |
| FLAb2.0,aggregation,CS-SINS (average),endpoint_c269a0398baa7c7f8a6d,43,43,1 |
| FLAb2.0,aggregation,CSI-BLI delta response (nm),endpoint_48de2886a09b2f81ba02,136,136,1 |
| FLAb2.0,aggregation,Fab pI,endpoint_ee4cad6271ec5d008c23,43,43,1 |
| FLAb2.0,aggregation,HIC relative retention time (RRT),endpoint_79cab82eaa56b5d0f458,13,13,1 |
| FLAb2.0,aggregation,HIC retention time (min),endpoint_9db79e57b5e3d93e303f,276,276,3 |
| FLAb2.0,aggregation,Heparin relative retention time (Rel RT),endpoint_f79ba2a3aefb6604f10d,127,127,1 |
| FLAb2.0,aggregation,NR-CGE main peak (%),endpoint_db6467c08db5fd506446,13,13,1 |
| FLAb2.0,aggregation,Red-CGE purity (%),endpoint_394b3f47bedc847a7fc5,13,13,1 |
| FLAb2.0,aggregation,SEC main peak (%),endpoint_4ed10dc629ed08057b5f,13,13,1 |
| FLAb2.0,aggregation,SEC monomer (%),endpoint_868e538870505b802eec,43,43,1 |
| FLAb2.0,aggregation,"SGAC-SINS AS100 ((NH4)2SO4, mM)",endpoint_93113c18fc2fceadc7dd,136,136,1 |
| FLAb2.0,aggregation,cIEF main peak (%),endpoint_0622707b9a6dbb6f88ee,43,43,1 |
| FLAb2.0,expression,Enrichment ratio (ER),endpoint_d43dfaca0142eeb5f0cb,15245,7078,2 |
| FLAb2.0,expression,Expression titer (µg/mL),endpoint_a678f7d88c79981723e4,94,94,1 |
| FLAb2.0,expression,HEK titer (mg/L),endpoint_576ea1afb35b038300ea,136,136,1 |
| FLAb2.0,immunogenicity,ADA response (%),endpoint_d0d899c2e5c302f0c7fa,213,208,1 |
| FLAb2.0,pharmacokinetics,FcRn cellular recycling (ng/mL),endpoint_0e6c8d8fc892c896f608,43,43,1 |
| FLAb2.0,pharmacokinetics,FcRn peak width (min),endpoint_ebdc283d64539232ab32,13,13,1 |
| FLAb2.0,pharmacokinetics,FcRn relative retention time (RRT),endpoint_2c8f92dcace1df3e9b8d,13,13,1 |
| FLAb2.0,pharmacokinetics,FcRn relative retention time (Rel RT),endpoint_c5f0250a9941ab564da2,131,131,1 |
| FLAb2.0,pharmacokinetics,FcRn retention time (min),endpoint_93b7f72f6348fc48aa06,13,13,1 |
| FLAb2.0,pharmacokinetics,Heparin retention time (min),endpoint_5007d53f45bcf2351a41,129,129,1 |
| FLAb2.0,pharmacokinetics,Sequence pI,endpoint_34a27267cb7414d79606,126,126,1 |
| FLAb2.0,pharmacokinetics,Tg32 clearance (mL/h/kg),endpoint_dff96be2a9ea9bafd730,43,43,1 |
| FLAb2.0,pharmacokinetics,Tg32 half-life (h),endpoint_581906274a4392b0aa2f,43,43,1 |
| FLAb2.0,polyreactivity,APC MFI,endpoint_f64d9009e3c235e10132,33,11,2 |
| FLAb2.0,polyreactivity,Anti-DNA binding (AU),endpoint_2fef3e139a79bf508ef0,13,13,1 |
| FLAb2.0,polyreactivity,Anti-DNP binding,endpoint_8973f28ae24cf5bbdd0d,112,112,1 |
| FLAb2.0,polyreactivity,BVP ELISA,endpoint_51b32deba56d0a0e09bb,136,136,1 |
| FLAb2.0,polyreactivity,CIC retention time (min),endpoint_70ef6588ddab0137beb0,174,153,5 |
| FLAb2.0,polyreactivity,ELISA (readout unspecified),endpoint_493fcb9beeb03bb29cb5,136,136,1 |
| FLAb2.0,polyreactivity,Fatty-acid binding (FA),endpoint_5a99f501f6c25e667339,113,113,1 |
| FLAb2.0,polyreactivity,Fe-induced binding (C3),endpoint_7527825afd9accb93af5,115,115,1 |
| FLAb2.0,polyreactivity,Fe-induced binding (FVIII),endpoint_14888b9daf1c40e73220,115,115,1 |
| FLAb2.0,polyreactivity,Fe-induced binding (LysM),endpoint_92632bb8bcb7f5ae492f,115,115,1 |
| FLAb2.0,polyreactivity,Fitness score,endpoint_96b83efe53174170854c,6,2,1 |
| FLAb2.0,polyreactivity,Heme binding,endpoint_435cd7d7f7b4e9ec688c,113,113,1 |
| FLAb2.0,polyreactivity,Heme-induced binding (C3),endpoint_2568d1b64180b0b0667b,113,113,1 |
| FLAb2.0,polyreactivity,Heme-induced binding (FVIII),endpoint_57636540d1b873118de2,113,113,1 |
| FLAb2.0,polyreactivity,Heme-induced binding (LysM),endpoint_1dbea562f24367ca90f5,113,113,1 |
| FLAb2.0,polyreactivity,Heparin relative retention time (Rel RT),endpoint_2af40527fff318914180,43,43,1 |
| FLAb2.0,polyreactivity,PSR score (0–1),endpoint_a6f2b2f76180b4e2cb2f,179,179,2 |
| FLAb2.0,polyreactivity,SMAC retention time (min),endpoint_e2e5992f30100f74ac4f,136,136,1 |
| FLAb2.0,polyreactivity,cELISA EC50 (pM),endpoint_6cd2a1ad45a28d31d349,13,13,1 |
| FLAb2.0,thermostability,DLS cumulant PDI,endpoint_a80415b5d1cc580501d4,13,13,1 |
| FLAb2.0,thermostability,DSF inflection point #1 (°C),endpoint_45f7290ecf61c4b67571,13,13,1 |
| FLAb2.0,thermostability,DSF inflection point #2 (°C),endpoint_d17de1d79a99339928a2,13,13,1 |
| FLAb2.0,thermostability,"Fab Tm (DSF, °C)",endpoint_fe99b1affc6188f82502,179,179,2 |
| FLAb2.0,thermostability,IgG Tm1 (°C),endpoint_94940642071338b5d9ab,258,206,4 |
| FLAb2.0,thermostability,Tm (unspecified),endpoint_61048569ecc285b59379,29,29,5 |
| FLAb2.0,thermostability,Tm (°C),endpoint_90990d24312811c18cb7,19,19,2 |
| FLAb2.0,thermostability,Tm1 (nanoDSF),endpoint_f8effa10c2cb1548a26f,86,86,1 |
| PROPHET-Ab,aggregation,AC-SINS_pH6.0,endpoint_cda627a686c7af649d50,242,241,1 |
| PROPHET-Ab,aggregation,AC-SINS_pH7.4,endpoint_d70560a40922671dc13a,242,241,1 |
| PROPHET-Ab,aggregation,HIC,endpoint_f7b52eb3b1efa8817438,242,241,1 |
| PROPHET-Ab,aggregation,Purity,endpoint_d0550bc30d749f1fae2c,242,241,1 |
| PROPHET-Ab,aggregation,SEC %Monomer,endpoint_dcb20491dd021967b969,242,241,1 |
| PROPHET-Ab,expression,Titer,endpoint_637c5db0643904baccce,239,238,1 |
| PROPHET-Ab,pharmacokinetics,HAC,endpoint_a1d04212c682731a7c45,94,93,1 |
| PROPHET-Ab,polyreactivity,PR_CHO,endpoint_6d065e1561136c40e311,197,196,1 |
| PROPHET-Ab,polyreactivity,PR_Ova,endpoint_fa0f09676a35d27be922,197,196,1 |
| PROPHET-Ab,polyreactivity,SMAC,endpoint_d377a8e327c23907e3d9,242,241,1 |
| PROPHET-Ab,thermostability,Tm1,endpoint_ed8de565c3269668e313,234,233,1 |
| PROPHET-Ab,thermostability,Tm2,endpoint_5004973a11c949f49093,193,192,1 |
| PROPHET-Ab,thermostability,Tonset,endpoint_5c5abdb4ada9385e7a8a,234,233,1 |
|
|
